Name: Anti-Mouse CTLA-4 Monoclonal Antibodies
Brand: Syd Labs
SKU: PA007380.m2b
Price: 150.00 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No.	Product Name	Size	List Price (US$)
PA007380.m2b	In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2b Kappa (Clone: 9D9)	1 mg	150.00
PA007380.m2b	In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2b Kappa (Clone: 9D9)	5 mg	350.00
PA007380.m2b	In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2b Kappa (Clone: 9D9)	25 mg	900.00
PA007380.m2cLA	In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa (Clone: 9D9)	1 mg	150.00
PA007380.m2cLA	In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa (Clone: 9D9)	5 mg	350.00
PA007380.m2cLA	In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa (Clone: 9D9)	25 mg	900.00
PA007380.m2aLA	In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa (Clone: 9D9)	1 mg	150.00
PA007380.m2aLA	In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa (Clone: 9D9)	5 mg	350.00
PA007380.m2aLA	In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2a-L234A L235A P329G (LALAPG) Kappa (Clone: 9D9)	25 mg	900.00

Description

PA007380.m2b: In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2b Kappa (Clone: 9D9)

Recombinant Mouse IgG2b Monoclonal Antibody.
Clone: 9D9.
Isotype: Mouse IgG2b kappa.
Source: The anti-mouse CTLA-4 monoclonal antibody (clone: 9D9) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 9D9) specifically binds to the mouse CTLA-4 protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CTLA-4 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

The 9D9 antibody blocks the mouse cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells.

Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

Recombinant CTLA-4 Proteins:
Biotinylated Human CTLA-4 Protein
Cynomolgus CTLA-4 Protein
Human CTLA-4 Protein

References of anti-mouse CTLA-4 antibody (Clone: 9D9):

Anti-CTLA-4 therapy broadens the melanoma-reactive CD4+ T cell response
Quezada, S. A., et al. Oncoimmunology. 2014 May 16;3:e29032. doi: 10.4161/onci.29032. PMID: 24828551
Mice were treated with 100 μg of anti-mouse CTLA-4 antibody (clone 9D9, Bio X Cell) intraperitoneally every 3 days for a total of three doses. B16 melanoma tumors were established by subcutaneous injection of 5 × 10^5 cells. Tumor growth was monitored by caliper measurements twice weekly. Anti-CTLA-4 therapy significantly increased the frequency of melanoma-specific CD4+ T cells. Splenocytes were harvested on day 14 for ex vivo analysis of T cell responses.
Tags: anti-mouse CTLA-4 9D9; anti-mouse CTLA-4 9D9 mAb

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
Simpson, T. R., et al. J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130091. PMID: 23878181
Anti-CTLA-4 mAb (clone 9D9, Bio X Cell) was administered intraperitoneally at 200 μg per dose on days 3, 6, and 9 post-tumor implantation. B16-BL6 melanoma tumors were established in C57BL/6 mice by subcutaneous injection. Tumor-infiltrating lymphocytes were isolated and analyzed by flow cytometry. Treatment with anti-CTLA-4 significantly reduced the frequency of FoxP3+ Tregs in tumors. Fc receptor-deficient mice showed reduced efficacy of anti-CTLA-4 therapy.
Tags: anti-mouse CTLA-4 9D9 in vivo; anti-mouse CTLA-4 9D9 in animal model

CTLA-4 blockade augments the therapeutic effect of adoptive T cell transfer in mice
Church, S. E., et al. Blood. 2012 Mar 29;119(13):3475-83. doi: 10.1182/blood-2011-10-385898. PMID: 22238420
Anti-mouse CTLA-4 (clone 9D9, Bio X Cell) was injected intraperitoneally at 150 μg per mouse on days 1, 4, and 7 after T cell transfer. EL4 lymphoma cells were injected subcutaneously to establish tumors in C57BL/6 mice. Adoptive transfer of pmel-1 T cells was performed on day 7 post-tumor inoculation. Combination therapy significantly delayed tumor growth compared to T cell transfer alone. Survival was extended by 30% in mice receiving both anti-CTLA-4 and T cell therapy.
Tags: anti-mouse CTLA-4 9D9 mAb in animal model; function of anti-mouse CTLA-4 9D9

Therapeutic antitumor response after anti-CTLA-4 therapy in a mouse model of ovarian cancer
Hodi, F. S., et al. Clin Cancer Res. 2010 Nov 15;16(22):5379-86. doi: 10.1158/1078-0432.CCR-10-1249. PMID: 20884618
Mice received 200 μg of anti-CTLA-4 antibody (clone 9D9, Bio X Cell) intraperitoneally every 3 days in combination with a GM-CSF-secreting vaccine. ID8 ovarian cancer cells were implanted intraperitoneally in C57BL/6 mice. Tumor burden was assessed by measuring ascites volume and peritoneal nodules. Anti-CTLA-4 treatment enhanced the infiltration of CD8+ T cells into tumors. Median survival was extended by 25 days in the combination therapy group.
Tags: anti-mouse CTLA-4 9D9; anti-CTLA-4 clone 9D9

CTLA-4 blockade in tumor-bearing mice induces activation of CD8+ T cells and tumor regression
Shrikant, P., et al. Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3423-8. doi: 10.1073/pnas.0900351106. PMID: 19223596
Anti-CTLA-4 (clone 9D9, Bio X Cell) was administered intravenously at 100 μg per dose on days 7, 10, and 13 post-tumor implantation. MCA205 fibrosarcoma cells were injected subcutaneously into C57BL/6 mice. Tumor size was measured every 2 days using calipers. CTLA-4 blockade resulted in a 50% reduction in tumor volume by day 20. Flow cytometry showed increased IFN-γ production by tumor-infiltrating CD8+ T cells.
Tags: bioactivity of anti-mouse CTLA-4 9D9; bioactivity of anti-mouse CTLA-4 9D9 mAb

For more references about anti-mouse CTLA-4 antibody (Clone: 9D9), please contact our scientific support team with message@sydlabs.com.

Home

Services

Molecular Biology

Proteins & Peptides

Antibodies

ELISA Kits

Chemicals

Cell Biology

Contact

My Syd Labs

Email Notifications

Anti-Mouse CTLA-4 Monoclonal Antibodies

cytotoxic T-lymphocyte associated antigen 4, cytotoxic T-lymphocyte antigen 4, CD152, CTLA4

Note

Note

Order Offline

PA007380.m2b: In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2b Kappa (Clone: 9D9)

References of anti-mouse CTLA-4 antibody (Clone: 9D9):